NCT03844750View on ClinicalTrials.gov

Preoperative Immunotherapy (Pembrolizumab) for Patients With Colorectal Cancer and Resectable Hepatic Metastases

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

July 22, 2019

Primary Completion Date

April 30, 2026

Study Completion Date

April 30, 2026

Conditions
Metastatic Malignant Neoplasm in the LiverStage IV Colorectal Cancer AJCC v8Stage IVA Colorectal Cancer AJCC v8Stage IVB Colorectal Cancer AJCC v8Stage IVC Colorectal Cancer AJCC v8
Interventions
PROCEDURE

Hepatectomy

Undergo liver resection.

BIOLOGICAL

Pembrolizumab

Given IV

DRUG

Vactosertib

Given orally

Trial Locations (1)

94143

University of California, San Francisco, San Francisco

Sponsors

Collaborators (1)

MedPacto, Inc.
All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

collaborator

MedPacto, Inc.

INDUSTRY

lead

Chloe Atreya, MD, PhD

OTHER

NCT03844750 - Preoperative Immunotherapy (Pembrolizumab) for Patients With Colorectal Cancer and Resectable Hepatic Metastases | Biotech Hunter | Biotech Hunter